Travere TherapeuticsTVTX
About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Employees: 380
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
47% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 49
5% more capital invested
Capital invested by funds: $704M [Q1] → $736M (+$32M) [Q2]
1% less funds holding
Funds holding: 172 [Q1] → 171 (-1) [Q2]
3% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 31
4.24% less ownership
Funds ownership: 119.85% [Q1] → 115.6% (-4.24%) [Q2]
52% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $3.75M
Research analyst outlook
23 Wall Street Analysts provided 1 year price targets over the past 3 months
23 analyst ratings
Scotiabank Greg Harrison 87% 1-year accuracy 13 / 15 met price target | 29%upside $23 | Sector Outperform Initiated | 16 Oct 2024 |
Leerink Partners Joseph Schwartz 71% 1-year accuracy 5 / 7 met price target | 124%upside $40 | Outperform Maintained | 11 Oct 2024 |
B of A Securities Greg Harrison 87% 1-year accuracy 13 / 15 met price target | 12%upside $20 | Buy Maintained | 9 Oct 2024 |
Guggenheim Vamil Divan 77% 1-year accuracy 10 / 13 met price target | 129%upside $41 | Buy Maintained | 9 Oct 2024 |
Wedbush Laura Chico 59% 1-year accuracy 41 / 70 met price target | 40%upside $25 | Outperform Maintained | 9 Oct 2024 |
Financial journalist opinion
Based on 42 articles about TVTX published over the past 30 days